Followers | 831 |
Posts | 120072 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
Tuesday, November 07, 2017 10:36:21 AM
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent CHRS News
- Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction • GlobeNewswire Inc. • 06/27/2024 12:26:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:57:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:55:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:54:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:52:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:51:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:47:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:46:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 01:11:23 PM
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors • GlobeNewswire Inc. • 06/05/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:05:13 PM
- Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 01:00:00 PM
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:51:06 PM
- Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA • GlobeNewswire Inc. • 05/23/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/21/2024 09:14:58 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2024 08:35:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:51:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:17:04 PM
- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:30:11 AM
- Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer • GlobeNewswire Inc. • 05/08/2024 01:00:00 PM
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 02:02:18 PM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM